Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.81M Buy
31,656
+1,508
+5% +$174K 0.84% 31
2025
Q4
$3.17M Sell
30,148
-262
-0.9% -$24.6K 0.71% 38
2025
Q3
$2.55M Sell
30,410
-1,156
-4% -$95.2K 0.59% 50
2025
Q2
$2.5M Sell
31,566
-2,859
-8% -$227K 0.52% 54
2025
Q1
$3.09M Sell
34,425
-1,822
-5% -$170K 0.68% 38
2024
Q4
$3.61M Sell
36,247
-1,032
-3% -$106K 0.79% 30
2024
Q3
$4.23M Buy
37,279
+70
+0.2% +$8.32K 0.92% 24
2024
Q2
$4.61M Buy
37,209
+44
+0.1% +$5.67K 1.07% 20
2024
Q1
$4.9M Sell
37,165
-627
-2% -$77.3K 1.19% 17
2023
Q4
$4.12M Buy
37,792
+854
+2% +$88.6K 1.14% 15
2023
Q3
$3.8M Buy
36,938
+576
+2% +$62.1K 1.16% 17
2023
Q2
$4.2M Buy
36,362
+1,513
+4% +$172K 1.28% 13
2023
Q1
$3.71M Buy
34,849
+3,585
+11% +$387K 1.28% 14
2022
Q4
$3.47M Buy
31,264
+2,495
+9% +$255K 1.47% 14
2022
Q3
$2.48M Buy
28,769
+3,944
+16% +$352K 1.19% 18
2022
Q2
$2.26M Buy
24,825
+181
+0.7% +$16K 1.01% 29
2022
Q1
$2.02M Buy
24,644
+3,549
+17% +$280K 0.72% 41
2021
Q4
$1.62M Buy
21,095
+927
+5% +$73.8K 0.63% 53
2021
Q3
$1.51M Buy
+20,168
New +$1.53M 0.59% 51

Other funds holding MRK

Herold Advisors's MRK Position: Q1 2026 in Review

Herold Advisors increased its Merck (MRK) stake by 5% in Q1 2026, buying an estimated $174K and bringing the position to 31,656 shares worth $3.81M. The position accounts for 0.84% of the portfolio, ranked #31.

Herold Advisors first reported a position in MRK in Q3 2021 and has held it in 19 quarters since. The position peaked at $4.9M in Q1 2024. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Herold Advisors held 31,656 shares of Merck worth $3.81M as of Q1 2026.
  • Herold Advisors bought 1,508 Merck shares in Q1 2026, an estimated $174K.
  • Merck made up 0.84% of Herold Advisors's portfolio in Q1 2026, its #31 holding.
  • Herold Advisors first reported a position in Merck in Q3 2021 and has held it in 19 quarters since.
  • Herold Advisors's Merck position peaked at $4.9M in Q1 2024.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Herold Advisors's 13F filing for Q1 2026, filed 15 May 2026.